Augmenta Bioworks has a total of 23 patents globally, out of which 3 have been granted. Of these 23 patents, more than 56% patents are active. United States of America is where Augmenta Bioworks has filed the maximum number of patents, followed by Japan and Europe. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Augmenta Bioworks.
Augmenta Bioworks was founded in the year 2016. The Company focuses on the individual’s immune profiling with the development of biologics therapeutics to treat various diseases.
Do read about some of the most popular patents of Augmenta Bioworks which have been covered by us in this article and also you can find Augmenta Bioworks patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Augmenta Bioworks patent portfolio.
How many patents does Augmenta Bioworks have?
Augmenta Bioworks has a total of 23 patents globally. These patents belong to 7 unique patent families. Out of 23 patents, 13 patents are active.
How Many Patents did Augmenta Bioworks File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Augmenta Bioworks Applications Filed | Augmenta Bioworks Patents Granted |
| 2023 | 1 | 2 |
| 2022 | 5 | – |
| 2021 | 2 | – |
| 2020 | 4 | 1 |
| 2019 | 4 | – |
| 2017 | 7 | – |
How many Augmenta Bioworks patents are Alive/Dead?
How Many Patents did Augmenta Bioworks File in Different Countries?
Countries in which Augmenta Bioworks Filed Patents
| Country | Patents |
| United States Of America | 9 |
| Japan | 2 |
| Europe | 2 |
| Canada | 1 |
| Australia | 1 |
| China | 1 |
Where are Research Centres of Augmenta Bioworks Patents Located?
The Research Centre for all the Augmenta Bioworks patents is the United States of America.
List of Augmenta Bioworks Patents
| Augmenta Bioworks Patents | Title |
| US11662341B2 | Methods For Isolating Immune Binding Proteins |
| US10858649B2 | Immune Repertoire Sequence Amplification Methods And Applications |
| US20230280332A1 | Methods For Isolating Immune Binding Proteins |
| US20230270668A1 | Dry Formulations Of Anti-Sars-Cov-2 Virus Antibodies And Compositions And Methods Of Use Thereof |
| US20220380746A1 | Methods For Making Gel Beads And Core And Shell Beads With A Cell |
| US20210347860A1 | Antibodies For Sars-Cov-2 And Uses Thereof |
| US20210079380A1 | Immune Repertoire Sequence Amplification Methods And Applications |
| US20200300861A1 | Isolation Of Single Cells And Uses Thereof |
| EP3512945A4 | Immune Repertoire Sequence Amplification Methods And Applications |
| JP7372387B2 | Immune Repertoire Sequence Amplification Methods And Applications |
| WO2023064717A3 | Antibodies For Sars-Cov-2 And Uses Thereof |
| WO2023064770A1 | Dry Formulations Of Anti-Sars-Cov-2 Virus Antibodies And Compositions And Methods Of Use Thereof |
| CA3032528A1 | Immune Repertoire Sequence Amplification Methods And Applications |
| US20200048626A1 | Methods For Making Gel Beads And Core And Shell Beads With A Cell |
| EP3941631A4 | Isolation Of Single Cells And Uses Thereof |
| CN110225972A | Immune Repertoire Sequence Amplification Methods And Applications |
| WO2021231237A3 | Antibodies For Sars-Cov-2 And Uses Thereof |
| WO2020198080A1 | Isolation Of Single Cells And Uses Thereof |
| WO2020077017A3 | Methods For Isolating Immune Binding Proteins |
| WO2020033332A1 | Methods For Making Gel Beads And Core And Shell Beads With A Cell |
| JP2019531091A | Immune Repertoire Sequence Amplification Method And Application |
| WO2018053119A3 | Immune Repertoire Sequence Amplification Methods And Applications |
| AU2017326338A1 | Immune Repertoire Sequence Amplification Methods And Applications |
What are Augmenta Bioworks key innovation segments?
What Technologies are Covered by Augmenta Bioworks?
The chart below distributes patents filed by Augmenta Bioworks